| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SEC22L1 |
| Uniprot No | 0 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-215 aa |
| 活性数据 | MVLLTMIARVADGLPLAASMQEDEQSGRDLQQYQSQAKQLFRKLNEQSPTRCTLEAGAMTFHYIIEQGVCYLVLCEAAFPKKLAFAYLEDLHSEFDEQHGKKVPTVSRPYSFIEFDTFIQKTKKLYIDSRARRNLGSINTELQDVQRIMVANIEEVLQRGEALSALDSKANNLSSLSKKYRQDAKYLNMRSTYAKLAAVAVFFIMLIVYVRFWWL |
| 分子量 | 49.39 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人SEC22L1蛋白的3篇模拟参考文献，涵盖其结构、功能及疾病关联研究：
---
1. **标题**：Crystal structure of human SEC22L1 reveals a conserved vesicular transport interface
**作者**：L. Chen et al.
**摘要**：本研究通过X射线晶体学解析了重组人SEC22L1蛋白的胞内结构域，揭示了其与其他SNARE蛋白(如Syntaxin-5)相互作用的保守界面，为SEC22L1在内质网-高尔基体囊泡运输中的膜融合机制提供结构依据。
2. **标题**：SEC22L1 modulates ER stress response via interaction with IRE1α in cancer cells
**作者**：M. Tanaka, S. R. Palade
**摘要**：研究发现，重组表达的SEC22L1蛋白通过结合内质网应激传感器IRE1α，调控肿瘤细胞中未折叠蛋白反应(UPR)，其敲低导致癌细胞对内质网应激诱导凋亡的敏感性增加，提示其作为癌症治疗的潜在靶点。
3. **标题**：Recombinant SEC22L1 reconstitutes SNARE complex formation in vitro
**作者**：G. Zhang et al.
**摘要**：通过体外重组表达SEC22L1、Bet1及Syntaxin-5.验证了其形成功能性SNARE复合体的能力，并证实复合体驱动脂质体膜融合，揭示SEC22L1在细胞内运输中的核心作用。
---
注：以上文献为示例性质，实际研究中需通过PubMed或Web of Science查询真实文献。
SEC22L1 (Sec22 homolog B, vesicle trafficking protein-like 1) is a member of the SEC22 family of vesicle transport proteins, which play critical roles in intracellular membrane trafficking. As a SNARE (soluble N-ethylmaleimide-sensitive factor attachment protein receptor) protein, SEC22L1 facilitates the fusion of transport vesicles with target membranes by forming specific complexes with other SNARE family members. It is primarily localized to the endoplasmic reticulum (ER) and ER-Golgi intermediate compartment (ERGIC), where it mediates anterograde and retrograde transport between the ER and Golgi apparatus.
Structurally, SEC22L1 contains a conserved SNARE motif, a transmembrane domain, and N-terminal regulatory regions. It interacts with syntaxin-5 and other SNARE proteins to regulate cargo sorting and vesicle docking. Emerging studies suggest its involvement in unconventional secretion pathways, autophagy, and organelle crosstalk, particularly under stress conditions. Dysregulation of SEC22L1 has been linked to cancer progression, neurodevelopmental disorders, and immune response modulation, likely through altered protein trafficking and signaling pathways.
Recombinant SEC22L1 protein is widely used to study membrane trafficking mechanisms in vitro. Produced via heterologous expression systems (e.g., E. coli or mammalian cells), it enables biochemical characterization of SNARE complex formation, lipid-binding properties, and interactions with trafficking regulators. This tool has advanced research on diseases associated with vesicular transport defects and therapeutic target discovery.
×
